Qiagen (NYSE:QGEN - Get Free Report) issued an update on its first quarter 2025 earnings guidance on Monday morning. The company provided earnings per share guidance of 0.550- for the period, compared to the consensus earnings per share estimate of 0.490. The company issued revenue guidance of $483.0 million-, compared to the consensus revenue estimate of $464.8 million. Qiagen also updated its FY 2025 guidance to 2.350- EPS.
Qiagen Trading Up 4.8 %
Qiagen stock traded up $1.93 during midday trading on Friday, reaching $41.98. The stock had a trading volume of 1,723,550 shares, compared to its average volume of 1,119,244. The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.38. The firm has a market cap of $9.33 billion, a price-to-earnings ratio of 116.88, a price-to-earnings-growth ratio of 2.39 and a beta of 0.62. Qiagen has a 52-week low of $37.63 and a 52-week high of $49.30. The company has a fifty day moving average of $39.75 and a 200 day moving average of $41.81.
Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. On average, analysts anticipate that Qiagen will post 2.26 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
QGEN has been the subject of a number of research reports. Morgan Stanley reiterated an "equal weight" rating and issued a $46.67 price target (down previously from $48.61) on shares of Qiagen in a report on Monday, January 6th. Robert W. Baird lowered Qiagen from an "outperform" rating to a "neutral" rating and cut their price target for the company from $52.00 to $42.00 in a research note on Wednesday, February 19th. UBS Group cut their price objective on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Baird R W lowered Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Finally, Redburn Atlantic lowered Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Eight equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, Qiagen has an average rating of "Hold" and a consensus price target of $47.71.
Get Our Latest Stock Analysis on Qiagen
Qiagen Company Profile
(
Get Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
Featured Articles
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
